PT3072906T - Formulação de anticorpos - Google Patents

Formulação de anticorpos

Info

Publication number
PT3072906T
PT3072906T PT161626999T PT16162699T PT3072906T PT 3072906 T PT3072906 T PT 3072906T PT 161626999 T PT161626999 T PT 161626999T PT 16162699 T PT16162699 T PT 16162699T PT 3072906 T PT3072906 T PT 3072906T
Authority
PT
Portugal
Prior art keywords
antibody formulation
antibody
formulation
Prior art date
Application number
PT161626999T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40637230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3072906(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT3072906T publication Critical patent/PT3072906T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PT161626999T 2008-12-10 2009-12-09 Formulação de anticorpos PT3072906T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08170884A EP2196476A1 (en) 2008-12-10 2008-12-10 Antibody formulation

Publications (1)

Publication Number Publication Date
PT3072906T true PT3072906T (pt) 2021-12-14

Family

ID=40637230

Family Applications (2)

Application Number Title Priority Date Filing Date
PT97648588T PT2376533T (pt) 2008-12-10 2009-12-09 Formulação de anticorpos
PT161626999T PT3072906T (pt) 2008-12-10 2009-12-09 Formulação de anticorpos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT97648588T PT2376533T (pt) 2008-12-10 2009-12-09 Formulação de anticorpos

Country Status (31)

Country Link
US (3) US20110236398A1 (OSRAM)
EP (4) EP2196476A1 (OSRAM)
JP (5) JP6143416B2 (OSRAM)
KR (2) KR101762966B1 (OSRAM)
CN (3) CN114225022A (OSRAM)
AU (1) AU2009324371B2 (OSRAM)
BR (1) BRPI0922730A2 (OSRAM)
CA (1) CA2745938C (OSRAM)
CL (1) CL2011001406A1 (OSRAM)
CO (1) CO6361952A2 (OSRAM)
CY (2) CY1117735T1 (OSRAM)
DK (2) DK2376533T3 (OSRAM)
EC (1) ECSP11011192A (OSRAM)
ES (2) ES2579835T3 (OSRAM)
HR (2) HRP20160754T1 (OSRAM)
HU (2) HUE028408T2 (OSRAM)
IL (3) IL264316B2 (OSRAM)
LT (1) LT3072906T (OSRAM)
MA (1) MA33023B1 (OSRAM)
MX (1) MX2011006242A (OSRAM)
MY (2) MY166050A (OSRAM)
NZ (1) NZ592918A (OSRAM)
PE (1) PE20120342A1 (OSRAM)
PL (2) PL2376533T3 (OSRAM)
PT (2) PT2376533T (OSRAM)
RU (2) RU2563179C2 (OSRAM)
SI (2) SI2376533T1 (OSRAM)
SM (1) SMT201600222B (OSRAM)
TN (1) TN2011000229A1 (OSRAM)
WO (1) WO2010066762A1 (OSRAM)
ZA (1) ZA201103362B (OSRAM)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
EP3216462A3 (en) 2010-02-26 2017-12-20 Novo Nordisk A/S Stable antibody containing compositions
HUE047173T2 (hu) 2010-03-01 2020-04-28 Bayer Healthcare Llc Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
MX351706B (es) 2010-09-17 2017-10-25 Baxalta Inc Estabilizacion de inmunoglobulinas a traves de una formulacion acuosa con histidina a ph acido debil a neutro.
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
TWI719112B (zh) 2011-03-16 2021-02-21 賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
FI123630B (fi) 2011-10-24 2013-08-30 Teknologian Tutkimuskeskus Vtt Menetelmä NFC-kalvojen valmistamiseksi alustoille
US20140348848A1 (en) 2011-12-02 2014-11-27 Dhananjay Kaul Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
ES2732243T3 (es) * 2012-02-16 2019-11-21 Santarus Inc Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
EP3539374A1 (en) * 2012-03-16 2019-09-18 Regeneron Pharmaceuticals, Inc. Non-human animals expressing ph-sensitive immunoglobulin sequences
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
CN109999195A (zh) * 2012-09-20 2019-07-12 莫弗系统股份公司 类风湿关节炎的治疗
CA2891556A1 (en) * 2012-11-16 2014-05-22 Novartis Ag Use of il-1 beta binding antibodies for treating peripheral arterial disease
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CN105025925A (zh) 2013-03-15 2015-11-04 拜尔健康护理有限责任公司 抗-催乳素受体抗体制剂
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
JP6707469B2 (ja) * 2014-05-28 2020-06-10 ノノ インコーポレイテッド アセチル化スカベンジャーを含むＴａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤
EP3188757A1 (en) * 2014-09-03 2017-07-12 Medimmune Limited Stable anti-il-4r-alpha antibody formulation
WO2016077451A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
BR112018010211A2 (pt) 2015-12-07 2019-02-05 Merck Patent Gmbh formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
CN115998859A (zh) * 2016-06-27 2023-04-25 莫佛塞斯公司 抗-cd19抗体制剂
WO2018015897A1 (en) * 2016-07-21 2018-01-25 Novartis Ag Use of the il-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis
KR102546471B1 (ko) * 2016-09-27 2023-06-21 프레제니우스 카비 도이치란트 게엠베하 액상의 약학 조성물
EP3543337B1 (en) 2016-11-18 2022-04-20 Astellas Pharma Inc. Novel anti-human muc1 antibody fab fragment
TW201904993A (zh) * 2017-06-22 2019-02-01 瑞士商諾華公司 IL-1β 結合抗體之用途
TWI795415B (zh) * 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
AU2018333106A1 (en) * 2017-09-13 2020-04-02 Novartis Ag Use of il-1b binding antibodies for the treatment of alcoholic hepatitis
EP3768706A1 (en) * 2018-03-23 2021-01-27 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
JP7360766B2 (ja) 2018-05-17 2023-10-13 アステラス製薬株式会社 抗ヒトＭＵＣ１抗体Ｆａｂフラグメント、ペプチドリンカー及び／又は配位子を含む複合体
JP7374544B2 (ja) 2018-10-10 2023-11-07 アステラス製薬株式会社 標識部－抗ヒト抗体Ｆａｂフラグメント複合体を含む医薬組成物
MA55033A (fr) 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
CN113967195A (zh) * 2020-07-22 2022-01-25 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体冻干制剂及其制备方法
US20240052026A1 (en) * 2020-12-22 2024-02-15 Bio-Thera Solutions, Ltd. Stable antibody formulation, preparation method therefor, and applications thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
DK1516628T3 (da) 1995-07-27 2013-09-08 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
NZ523080A (en) * 2000-06-29 2004-11-26 Abbott Lab Antibodies specific for interleukin-1 alpha and interleukin-2 beta and methods of making and using
JP5490972B2 (ja) * 2000-08-04 2014-05-14 中外製薬株式会社 タンパク質注射製剤
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
CA2466034C (en) * 2001-11-08 2012-12-18 Protein Design Labs, Inc. Stable aqueous pharmaceutical formulations of daclizumab antibodies
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
BRPI0403964B8 (pt) * 2003-04-04 2021-05-25 Genentech Inc formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige
PA8661401A1 (es) * 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
AR054233A1 (es) * 2005-03-08 2007-06-13 Pharmacia & Upjohn Co Llc Composiciones de anticuerpos igg2
AU2006247039B2 (en) * 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
WO2007050607A2 (en) 2005-10-26 2007-05-03 Novartis Ag Novel use of il-1beta compounds
CN201044845Y (zh) * 2006-10-28 2008-04-09 李开元 自动注射器
KR20090104017A (ko) * 2006-12-11 2009-10-05 에프. 호프만-라 로슈 아게 Ａ베타 항체 비경구 제제
EP2136839A4 (en) * 2007-03-22 2010-04-07 Imclone Llc STABLE ANTIBODY FORMULATIONS
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery

Also Published As

Publication number Publication date
RU2015132431A (ru) 2018-12-24
EP2376533A1 (en) 2011-10-19
RU2563179C2 (ru) 2015-09-20
PL2376533T3 (pl) 2016-09-30
EP2376533B1 (en) 2016-03-30
ECSP11011192A (es) 2011-08-31
JP7286595B2 (ja) 2023-06-05
IL212922A0 (en) 2011-07-31
TN2011000229A1 (en) 2012-12-17
RU2015132431A3 (OSRAM) 2018-12-24
CL2011001406A1 (es) 2012-03-30
CA2745938C (en) 2018-04-24
JP2020203889A (ja) 2020-12-24
CN102245639A (zh) 2011-11-16
EP3792282A1 (en) 2021-03-17
EP3072906B1 (en) 2021-09-08
MA33023B1 (fr) 2012-02-01
JP6143416B2 (ja) 2017-06-07
ES2900624T3 (es) 2022-03-17
BRPI0922730A2 (pt) 2018-11-06
CN104399076B (zh) 2021-09-14
KR101762966B1 (ko) 2017-07-31
CN102245639B (zh) 2014-12-24
SI3072906T1 (sl) 2022-01-31
AU2009324371B2 (en) 2013-10-10
RU2745601C2 (ru) 2021-03-29
EP3072906A1 (en) 2016-09-28
KR20120009421A (ko) 2012-01-31
IL276622A (en) 2020-09-30
HRP20160754T1 (hr) 2016-08-12
PT2376533T (pt) 2016-07-13
JP2012511540A (ja) 2012-05-24
CA2745938A1 (en) 2010-06-17
PL3072906T3 (pl) 2022-01-24
EP2196476A1 (en) 2010-06-16
CY1117735T1 (el) 2017-05-17
MX2011006242A (es) 2011-06-24
JP2015231997A (ja) 2015-12-24
MY166050A (en) 2018-05-22
ES2579835T3 (es) 2016-08-17
US20120315285A1 (en) 2012-12-13
JP2023109938A (ja) 2023-08-08
IL212922B (en) 2019-02-28
HUE056626T2 (hu) 2022-02-28
JP2018168158A (ja) 2018-11-01
AU2009324371A1 (en) 2011-06-23
DK3072906T3 (da) 2021-12-13
RU2011127913A (ru) 2013-01-20
US20200384108A1 (en) 2020-12-10
SI2376533T1 (sl) 2016-07-29
LT3072906T (lt) 2021-12-27
US20110236398A1 (en) 2011-09-29
PE20120342A1 (es) 2012-04-24
CO6361952A2 (es) 2012-01-20
CN114225022A (zh) 2022-03-25
KR20170044211A (ko) 2017-04-24
SMT201600222B (it) 2016-08-31
DK2376533T3 (en) 2016-06-27
HUE028408T2 (en) 2016-12-28
IL264316A (en) 2019-02-28
HK1159130A1 (zh) 2012-07-27
IL264316B2 (en) 2024-01-01
ZA201103362B (en) 2012-01-25
CN104399076A (zh) 2015-03-11
IL264316B1 (en) 2023-09-01
MY157772A (en) 2016-07-29
NZ592918A (en) 2012-12-21
HRP20211899T1 (hr) 2022-03-04
CY1124844T1 (el) 2022-11-25
WO2010066762A1 (en) 2010-06-17
US8623367B2 (en) 2014-01-07

Similar Documents

Publication Publication Date Title
IL276622A (en) Antibody formulation
HRP20181868T1 (hr) Anti-cmet antitijelo
EP2077859A4 (en) ANTIBODY FORMULATION
IL206103A0 (en) Antibody formulation
ZA201101343B (en) Novel antibody formulation
ZA201204266B (en) Antibody formulation
ZA201106503B (en) Antibody formulation
ZA201203242B (en) Antibody formulation
EP2241578A4 (en) ANTI-CLDN6 ANTIBODIES
ZA201102119B (en) Improved antibody libraies
GB0822633D0 (en) Formulation
ZA201004772B (en) Novel formulation
GB0814376D0 (en) Formulation
GB0911770D0 (en) Antibody
GB0817622D0 (en) Antibody
GB0817621D0 (en) Antibody
HK1162914A (en) Antibody formulation
GB0806445D0 (en) Formulation
GB0817663D0 (en) Formulation
GB0819113D0 (en) An antibody
HK1166087A (en) Antibody formulation